Health Sector Mood Turns Cautious on FDA Shifts

People currently seem to think the FDA will not reclassify a key benchmark on the Bulk Drug Substances List by August. The mood here feels overwhelmingly skeptical, with most leaning toward No.

Expectations appear to be leaning No as well for a December timeline. The feeling is more divided now, though a slight edge still favors No.

Heidi Overton's confirmation as FDA Commissioner is another hot topic. Current feeling clearly favors No for a September deadline. By October, the mood still leans toward No. November brings no change, with expectations remaining doubtful.

Overall, the health sector seems cautious. People are divided but mostly doubtful about major FDA moves happening soon. The mood feels weakening for big changes.